CME Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.62B

+6.53%

2.718

+7.87%

1.67B

+1.54%

2.906

+3.78%

1.69B

+0.01%

2.959

-0.03%

Estimates Revision

The market is revising Upward the revenue expectations for CME Group Inc. (CME) for FY2025, with the revenue forecasts being adjusted by 0.29% over the past three months. During the same period, the stock price has changed by -0.82%.

Revenue Estimates for FY2025

Revise Upward

+0.29%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.83%

In Past 3 Month

Stock Price

Go Down

-0.82%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast CME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CME is 284.58 USD with a low forecast of 201.00 USD and a high forecast of 314.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

4 Hold

2 Sell

Moderate Buy

Current: 0.000

Low

201.00

Averages

284.58

High

314.00

Current: 0.000

Low

201.00

Averages

284.58

High

314.00

Morgan Stanley

Michael Cyprys

Overweight

maintain

$314 -> $320

2025-12-22

Reason

Morgan Stanley

Michael Cyprys

Price Target

$314 -> $320

2025-12-22

maintain

Overweight

Reason

Morgan Stanley analyst Michael Cyprys raised the firm's price target on CME Group to $320 from $314 and keeps an Overweight rating on the shares. Healthy transactional activity across brokers and exchanges in Q4 drives modest positive revision risk, notes the analyst in a preview. The analyst is raising Q4 EPS estimates by 5% on average, leaving the firm in-line with consensus, the analyst noted.

Barclays

Equal Weight

maintain

$280 -> $304

2025-12-12

Reason

Barclays

Price Target

$280 -> $304

2025-12-12

maintain

Equal Weight

Reason

Barclays raised the firm's price target on CME Group to $304 from $280 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the brokers, asset managers and exchanges group as part of its 2026. Market conditions "look constructive" going into 2026, particularly for the alternative asset managers and wealth brokers, the analyst tells investors in a research note. Barclays sees a more mixed outlook for the exchanges and traditional asset managers.

BofA

Underperform

maintain

$201 -> $209

2025-12-10

Reason

BofA

Price Target

$201 -> $209

2025-12-10

maintain

Underperform

Reason

BofA raised the firm's price target on CME Group to $209 from $201 and keeps an Underperform rating on the shares. Looking ahead to 2026, the firm now favors the alternative asset managers to online brokers due to what it sees as a better valuation and positioning setup combined with a stronger macro backdrop, the analyst tells investors in a note on the brokers, asset managers and exchanges group.

BofA

Craig Siegenthaler

Underperform

downgrade

$204 -> $201

2025-10-24

Reason

BofA

Craig Siegenthaler

Price Target

$204 -> $201

2025-10-24

downgrade

Underperform

Reason

BofA analyst Craig Siegenthaler lowered the firm's price target on CME Group to $201 from $204 and keeps an Underperform rating on the shares. Q3 volume was soft with sequential declines in all asset classes as a result of lower market volatility and seasonality, the analyst tells investors in a post-earnings note. The firm is lowering its Q4, 2026 and 2027 EPS estimates due to modest upward revisions to taxes and expenses, the analyst noted.

UBS

Alex Kramm

Neutral

downgrade

$285 -> $280

2025-10-23

Reason

UBS

Alex Kramm

Price Target

$285 -> $280

2025-10-23

downgrade

Neutral

Reason

UBS analyst Alex Kramm lowered the firm's price target on CME Group to $280 from $285 and keeps a Neutral rating on the shares. The firm sees "no shortage of initiatives" at CME, but argues that the near-term volume picture "remains tough."

Morgan Stanley

Michael Cyprys

Overweight

maintain

$312 -> $314

2025-10-23

Reason

Morgan Stanley

Michael Cyprys

Price Target

$312 -> $314

2025-10-23

maintain

Overweight

Reason

Morgan Stanley analyst Michael Cyprys raised the firm's price target on CME Group to $314 from $312 and keeps an Overweight rating on the shares. With 80% of revenues derived from clearing and transaction fees, and a "strong moat" around its futures and options complex, the firm views CME as "best placed" in a period of ongoing macro uncertainty and renewed credit concerns, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for CME Group Inc (CME.O) is 23.59, compared to its 5-year average forward P/E of 24.43. For a more detailed relative valuation and DCF analysis to assess CME Group Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

24.43

Current PE

23.59

Overvalued PE

28.21

Undervalued PE

20.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

20.86

Current EV/EBITDA

20.81

Overvalued EV/EBITDA

23.41

Undervalued EV/EBITDA

18.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

13.94

Current PS

14.62

Overvalued PS

15.50

Undervalued PS

12.38

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CME News & Events

Events Timeline

No data

News

9.5

01-08NASDAQ.COM

Johnson & Johnson's Innovative Medicine Growth Strong, MedTech Improves

7.5

01-08PRnewswire

CME Group Reports Record 8.4M International ADV in 2025, Up 8%

4.5

01-07NASDAQ.COM

XLF ETF Reaches 52-Week High of $56.51 Amid Trading Insights

People Also Watch

Frequently Asked Questions

What is CME Group Inc (CME) stock price today?

The current price of CME is 266.64 USD — it has decreased -0.08 % in the last trading day.

What is CME Group Inc (CME)'s business?

CME Group Inc. provides a derivatives marketplace. The Company enables clients to trade futures, options, cash and over the counter (OTC) markets, optimize portfolios, and analyze data. It exchanges offer a range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange (FX), energy, agricultural products and metals. It offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and FX trading on the EBS platform. In addition, it operates central counterparty clearing provider, CME Clearing. Its products provide a means for hedging, speculation and asset allocation related to the risks associated with, among other things, interest rate sensitive instruments, and changes in the prices of agricultural, energy and metal commodities. It provides clearing and settlement services for a range of exchange-traded futures and options on futures contracts and OTC derivatives.

What is the price predicton of CME Stock?

What is CME Group Inc (CME)'s revenue for the last quarter?

CME Group Inc revenue for the last quarter amounts to 3.09B USD, increased 18.19 % YoY.

What is CME Group Inc (CME)'s earnings per share (EPS) for the last quarter?

CME Group Inc. EPS for the last quarter amounts to 2.49 USD, decreased -0.40 % YoY.

What changes have occurred in the market's expectations for CME Group Inc (CME)'s fundamentals?

How many employees does CME Group Inc (CME). have?

CME Group Inc (CME) has 3760 emplpoyees as of January 09 2026.

What is CME Group Inc (CME) market cap?

Today CME has the market capitalization of 96.15B USD.